Replies to post #694 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Minor correction: EDP-239 is not host-targeted—it’s an NS5A inhibitor. However, ENTA does have a (host-targeted) cyclophilin inhibitor in preclinical development that would make a logical companion for EDP-239 in a 2-drug cocktail wholly owned by ENTA.

[willyw]

Correction;

(I wrote)
--------------------------------------
FWIW, the Harvoni pill is 400 mg. So an Abbvie 530 dose would need to be about 200 mg to be the exact same size as Harvoni at 1 pill per day.
------------------------------------------

The correct dosing of Harvoni is 400 mg of Sofosbuvir/ 90 mg Ledipasvir, so the total in one pill is 490 mg.